reason report
bottom line us remain attract diagnost stori
three classifi test reduc diagnost uncertainti
patient biopharma collabor augment core
busi post solid result reiter guid
deliv revenu growth ex-biopharma payment
power three test franchis afirma percepta
envisia despit strong result highlight quarter
data releas non-invas nasal swab classifi
lung cancer chest confer see set
roughli doubl target nasarisk
expect launch identifi patient
low-risk bucket patient high-risk
bucket compar current standard care current assay
continu strong momentum total genom test volum
prior year pulmonari portfolio percepta
envisia repres overal volum reiter op
rate pt
classifi help address post ct work-up burden cost
nasal swab test help inform treatment decis pulmonologist
see patient suspici nodul detect low dose ct
scan patient nodul manag
estim approxim suspici enough refer
pulmonologist work-up roughli would end
cancer would benign accord
data releas american colleg chest physician chest
annual meet meet nasal test classifi
benign patient low risk sensit
malign patient high risk specif typic pool
patient suspici nodul test classifi roughli half
patient high low risk reduc patient indetermin
intermedi risk categori half help reduc unnecessari
costli workup see roughli test
anoth eu ad estim ww opportun
flagship afirma product continu strong growth thyroid
cancer afirma genom classifi test volum grew
emerg standard care indetermin thyroid
cancer biopsi remain track deliv close afirma
test integr sale strategi
continu aid adopt number account use least one
product grew almost account estim
increment penetr afirma lead steadi
double-digit revenu growth compani lead test franchis
compani inform svb leerink llc research
revenu million
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
emerg lung portfolio percepta envisia repres
roughli overal volum percepta genom sequenc
classifi address inconclus bronchoscopi deliv test
revenu prior year believ
percepta volum asp improv hold opportun growth
ahead penetr increas reimburs strengthen
time envisia assay detect idiopath pulmonari fibrosi
ipf grow rapidli earli day volum nearli doubl
sequenti test track deliv test full
year manag hope leverag presenc lung diseas
launch nasal swab test
rate share outperform price target
address company-estim diagnost market via neg classifi test help
reduc ambigu diagnosi sizabl subset thyroid lung cancer patient well
dramat reduc unnecessari surgeri vcyt test improv diagnosi save
healthcar cost believ pose signific valu provid payer
value-driven healthcar landscap develop proprietari express test
afirma identifi benign thyroid nodul indetermin tradit cytolog help
physician patient confid forgo unnecessari thyroid surgeri afirma believ
path becom standard care given thyroid fna
fine needl aspir found indetermin year suitabl test
afirma alreadi driven near penetr market compani expect
reach longer term company-estim market market
veracyt second test percepta bronchial gene express classifi
neg predict valu help identifi patient consid low risk initi
bronchoscopi result found inconclus help reduc unnecessari surgeri
save overal cost system percepta bronchial classifi address
bronchoscopi everi year lung nodul reveal ct inconclus
case drive market opportun percepta test
annual market reimburs medicar continu garner
also commerci envisia third test neg classifi test idiopath
pulmonari fibrosi ipf drive total address market three diagnost test
believ reimburs continu import driver revenu
beyond test volum compani continu build stronger payer base time
gain increasingli cover contract live drive adopt test
vcyt multi-year collabor innov earli stage discoveri therapeut arm
global lung cancer initi develop non-invas nasal swab diagnost
test lung cancer valid potenti field injuri approach posit
part collabor receiv payment addit
follow futur clinic studi grow reveal data non-invas nasal
swab octob show test risk classifi patient suspici
lung nodul manag estim market opportun eu
combin opportun compani plan begin make test avail earli
multipl shot goal prove technolog model address
inconclus biopsi longer term believ adopt vcyt gene express
test cancer thyroid nodul lung bronchi continu increas
data reimburs updat pipelin offer addit catalyst addit believ
vcyt manag team includ ceo bonni anderson proven execut
ramp maxim revenu shift reimburs landscap
share current trade ev/sal diagnost peer
qtnt gh ghdx ttoo multipl averag given higher rate
reimburs afirma becom standard care market newli launch
test includ percepta envisia gain traction next year back strong clinic
data biopharma revenu ramp believ share could trade discount
higher growth peer realiz least ev/sal estim result pt
primari risk price target includ limit reimburs
rate decis move forward visibl test includ percepta envisia fda
regul financ commit given neg cash flow near term
declin reimburs could sever impact revenu major risk
reimburs rate could decreas dramat current reimburs rate
among highest industri much revenu base
reimburs rate impact amount test administ adopt rate
exist new test vcyt ramp would sever impact refil reject
even wors reimburs rate continu fall given still early-stag compani
visibl still somewhat limit despit encourag sign still early-stag
compani neg net incom provid progress report afirma
encourag result test gain traction howev still plenti uncertainti
busi given model still show neg earn least busi
develop forecast expect face challeng new compani face
competit disadvantag limit visibl
fda regul remain risk regulatori concern fda decis
impact product still earli stage ramp envisia
could impact fda given nascent natur test fda regul could impact
product number product offer compani increas regul
fda would requir addit sg expens satisfi complianc increas cost
could also affect abil ramp
addit financ could still happen posit cash flow come later expect
possibl may need addit financ given expect neg net incom
near term expect posit cash flow come later expect compani
need anoth round financ exist debt could lead addit interest expens
increas net debt balanc sheet could also lead increas capit cost
servic
interest expens incom net
sg sale
 sale
oper expens sale
compani report svb leerink estim
